Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rapid test may cut time on wrong antibiotics after lung transplant

NCT ID NCT07792018

Diagnosis Sponsor: Assistance Publique Hopitaux De Marseille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial tests whether a rapid test called FilmArray Pneumonia Plus Panel (FAPP) can help doctors adjust antibiotics sooner after a lung transplant. The test identifies bacteria in respiratory samples within about 4 hours, compared to standard cultures that take 3 to 5 days. Researchers will compare patients whose antibiotic treatment is guided by FAPP results to those receiving usual care. The goal is to see if the test reduces the time patients spend on antibiotics that do not cover the bacteria present, potentially lowering the risk of infections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FilmArray Pneumonia Plus Panel (FAPP), a rapid diagnostic test that identifies respiratory bacteria in about 4 hours
What this could lead to
If it works, this rapid test could help doctors choose the right antibiotics sooner after lung transplant, lowering the risk of severe infections.
What could go wrong
The test may not always match standard lab cultures, and the trial is relatively small, so results may not apply to all transplant patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 98 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Nov 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patient, aged 18 years or over, * Patients who have given their written informed consent to participate in the study, * Patients registered on the lung transplant list, * Patients who are a beneficiary or entitled to a social security scheme Exclusion Criteria: * Patient for whom a combined transplant (i.e. combining lung transplantation with another organ transplant) is planned, * Patient in a period of exclusion from another research protocol at the time of signing consent, * Patients covered by Articles L1121-5 to 1121-8 of the Public Health Code (minor patient, adult patient under guardianship or curatorship, patient deprived of liberty, pregnant or breastfeeding woman).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung transplantation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung transplantation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.